Literature DB >> 11252332

The control of hyperendemic glycopeptide-resistant Enterococcus spp. on a haematology unit by changing antibiotic usage.

S J Bradley1, A L Wilson, M C Allen, H A Sher, A H Goldstone, G M Scott.   

Abstract

The rectal carriage of glycopeptide-resistant Enterococcus spp. (GRE) had been established at approximately 50% in a series of prevalence studies on a busy haematological malignancy unit. The aim of this study was to reduce the chance of patients acquiring GRE. A prospective three-phase sequential study was performed. In Phase 1, the acquisition rate of GRE detectable by rectal swab was measured without any intervention for a period of 4 months. For the following 8 months (Phase 2), the first-line treatment for febrile neutropenic episodes was changed from monotherapy with ceftazidime to piperacillin/tazobactam. In addition, an intense education programme was introduced to improve hygiene to reduce the risk of case-to-case spread. In the final 4 months (Phase 3), ceftazidime was again used as the first-line antimicrobial, while continuing the same level of training in relation to hygiene. The carriage of GRE was measured from rectal swabs done weekly. During the initial 4 months, at any time, 40-50% of patients in the unit were colonized with GRE, and 43 of 75 (57%) new patients initially negative for GRE acquired it within 6 weeks of their admission. In Phase 2, 25 patients out of 129 (19%) acquired GRE, with the acquisition rate falling progressively so that in the last 3 months, only one new patient acquired GRE (logrank comparison of probabilities for cohort 1 vs cohort 2b: P < 0.0001). A return to ceftazidime in Phase 3 was associated with a return of the risk of acquiring detectable GRE colonization, despite continued hygiene teaching and surveillance, with 21 out of 58 patients (36%) acquiring GRE (cohort 1 vs cohort 3: P = 0.08). Glycopeptide usage was not reduced during the period of the study. Clinical cases were seen only in Phases 1 and 3. Although the reduction in the risk of acquiring GRE may have been due in part to hygiene practices as well as to the change in antimicrobial usage, or may have occurred spontaneously for other reasons, the return of the problem with the reintroduction of ceftazidime strongly suggests that this antibiotic was responsible for encouraging the acquisition of detectable GRE.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 11252332     DOI: 10.1093/jac/43.2.261

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  23 in total

Review 1.  Effects of antibiotics on nosocomial epidemiology of vancomycin-resistant enterococci.

Authors:  Stephan Harbarth; Sara Cosgrove; Yehuda Carmeli
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

2.  Association between vancomycin-resistant Enterococci bacteremia and ceftriaxone usage.

Authors:  James A McKinnell; Danielle F Kunz; Eric Chamot; Mukesh Patel; Rhett M Shirley; Stephen A Moser; John W Baddley; Peter G Pappas; Loren G Miller
Journal:  Infect Control Hosp Epidemiol       Date:  2012-05-14       Impact factor: 3.254

3.  Coagulase-negative staphylococci: comparison of phenotypic and genotypic oxacillin susceptibility tests and evaluation of the agar screening test by using different concentrations of oxacillin.

Authors:  Rosana B R Ferreira; Natalia L P Iorio; Karoline L Malvar; Ana Paula F Nunes; Leila S Fonseca; Carla C R Bastos; Kátia R N Santos
Journal:  J Clin Microbiol       Date:  2003-08       Impact factor: 5.948

Review 4.  Antibiotics and gastrointestinal colonization by vancomycin-resistant enterococci.

Authors:  L B Rice
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-12       Impact factor: 3.267

Review 5.  Piperacillin/tazobactam: a pharmacoeconomic review of its use in moderate to severe bacterial infections.

Authors:  M Young; G L Plosker
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

Review 6.  Clinical role of beta-lactam/beta-lactamase inhibitor combinations.

Authors:  Nelson Lee; Kwok-Yung Yuen; Cyrus R Kumana
Journal:  Drugs       Date:  2003       Impact factor: 9.546

7.  Acquisition of rectal colonization by vancomycin-resistant Enterococcus among intensive care unit patients treated with piperacillin-tazobactam versus those receiving cefepime-containing antibiotic regimens.

Authors:  David L Paterson; Carlene A Muto; Magdaline Ndirangu; Peter K Linden; Brian A Potoski; Blair Capitano; Robert A Bonomo; David C Aron; Curtis J Donskey
Journal:  Antimicrob Agents Chemother       Date:  2007-11-19       Impact factor: 5.191

Review 8.  Three decades of beta-lactamase inhibitors.

Authors:  Sarah M Drawz; Robert A Bonomo
Journal:  Clin Microbiol Rev       Date:  2010-01       Impact factor: 26.132

Review 9.  Antimicrobial agent exposure and the emergence and spread of resistant microorganisms: issues associated with study design.

Authors:  C Angebault; A Andremont
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-12-27       Impact factor: 3.267

Review 10.  [Collateral damage of cephalosporins and quinolones and possibilities for control].

Authors:  Fuat H Saner; Ali Canbay; Guido Gerken; Christoph E Broelsch
Journal:  Med Klin (Munich)       Date:  2009-02-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.